Aegerion Pharmaceuticals Presents One-Year Data For LOWER Study

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has presented one-year data from the company’s Lomitapide Observational Worldwide Evaluation Registry (LOWER) study.

According to the press release, this study:

Showed safety and efficacy results consistent with those observed in the pivotal study of lomitapide in adult patients with homozygous familial hypercholesterolemia (HoFH). There were no new safety signals. Lomitapide, marketed as JUXTAPID® capsules in the U.S., is a microsomal triglyceride transfer protein inhibitor indicated in the U.S. as an adjunct to a low-fat diet and other lipid lowering treatments, including apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B) and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with HoFH. Lomitapide is also approved, with a comparable indication, under the brand name LOJUXTA® in the European Union.

LOWER is a global, long-term, prospective, observational registry of the long-term safety and effectiveness of lomitapide in clinical practice. These and future data from LOWER will provide further information about the  long-term safety and effectiveness of lomitapide in a real world setting. At least 300 patients treated with lomitapide in a commercial setting will be followed for a minimum of 10 years. These data were presented in a poster entitled “Lomitapide Observational Worldwide Evaluation Registry (LOWER): One-Year Data” at the 2015 American Heart Association’s (AHA) Scientific Sessions in Orlando, Florida.

Click here to read the full press release.